Choose Ozempic (Semaglutide) If: You have type 2 diabetes and established cardiovascular disease semaglutide has a proven cardiovascular benefit (SUSTAIN-6 trial) You have pre-existing diabetic retinopathy requiring more gradual glucose reduction You have chronic kidney disease semaglutide has an approved kidney-protective indication Your insurance covers semaglutide but not tirzepatide Choose Mounjaro (Tirzepatide) If: Maximum weight loss is your primary goal the data consistently and significantly favours tirzepatide You have type 2 diabetes with persistently poor blood glucose control Your insurance or savings programme makes tirzepatide accessible at a similar cost You have PCOS with significant insulin resistance the dual GLP-1/GIP mechanism produces particularly meaningful improvements in HOMA-IR
GLP-1 receptor agonists work on GLP-1 receptors, which are located throughout your body, including in your brain and central nervous system, Varisco explains
Proper adherence supports swift approval, safe administration, and global availability, helping patients worldwide achieve significant weight loss and improved metabolic health through high-quality, long-acting GLP-1 receptor agonist therapies
When Semaglutide is administered, it binds to GLP-1 receptors located on various target tissues, including pancreatic beta cells, which are responsible for producing insulin
Halima BH, Sonia G, Sarra K, Houda BJ, Fethi BS, Abdallah A
It worsens when you stand quickly, skip meals, or become dehydrated, and improves noticeably when you drink water or eat a small carbohydrate
